Pfizer's animal health unit Zoetis prices IPO at $26, above the range

By
A A A

Zoetis, a spin-off of Pfizer's global animal health medicines and vaccines business, raised $2.2 billion by offering 86.1 million shares at $26, above the range of $22 to $25. Zoetis plans to list on the NYSE under the symbol ZTS. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: ZTS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Quick on Your Feet
Quick on Your Feet                  
Early Entrepreneurship
Early Entrepreneurship              

Stocks

Referenced

100%

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com